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Capsule  
Background: Sharp-1 inhibits skeletal muscle 
differentiation.  
Results:  SUMO modification impacts of 
Sharp-1 mediated inhibition of 
myogenesis. 
Conclusion:  Sumoylation acts as a signal for 
recruitment of the chromatin 
modifier G9a.  
Significance: These studies link sumoylation 
with chromatin structure and 
myogenic differentiation.    
Summary 
Sumoylation is an important post-translational 
modification that alters the activity of many 
transcription factors. However, the mechanisms 
which link sumoylation to alterations in 
chromatin structure that culminate in tissue 
specific gene expression are not fully understood.  
In this study, we demonstrate that SUMO 
modification of the basic helix-loop-helix 
transcription factor Sharp-1 is required for its 
full transcriptional repression activity and 
function as an inhibitor of skeletal muscle 
differentiation. Sharp-1 is modified by 
sumoylation at two conserved lysine residues 
240 and 255. Mutation of these SUMO acceptor 
sites in Sharp-1 does not impact its sub-cellular 
localization, but attenuates its ability to act as a 
transcriptional repressor and inhibit myogenic 
differentiation. Consistently, co-expression of 
the SUMO protease SENP1 with wild type 
Sharp-1 abrogates Sharp-1 dependent inhibition 
of myogenesis. Interestingly, sumoylation acts 
as a signal for recruitment of the co-repressor 
G9a. Thus, enrichment of histone H3 lysine 9 
dimethylation (H3K9me2), a signature of G9a 
activity, is dramatically reduced at muscle 
promoters in cells expressing sumoylation 
defective Sharp-1 compared to wild type Sharp-
1. Our findings demonstrate how sumoylation of 
Sharp-1 exerts an impact on chromatin structure, 
and transcriptional repression of muscle gene 
expression through recruitment of G9a. 
 
Introduction 
Small Ubiquitin-like Modifier (SUMO) 
is one of the best-characterized members of 
ubiquitin-like proteins involved in regulation of 
transcription factors (1-3). There are four SUMO 
isoforms in mammals (SUMO-1, SUMO-2 
SUMO-3 and SUMO-4). Like ubiquitin, SUMO 
is also ligated to lysine residues in target 
proteins, and the target lysine usually embedded 
within a canonical consensus ΨKXE, where Ψ is 
a hydrophobic amino acid, K is the acceptor 
lysine for covalent conjugation of SUMO, X is 
any amino acid and E is glutamic acid. SUMO is 
covalently attached to substrates through the 
activities of an enzyme cascade similar to the 
ubiquitination cycle: SUMO is activated by the 
E1 activation enzyme, transferred to the sole E2 
enzyme Ubc9, which then conjugates to the 
substrate by a specific E3 ligase. Proteins from 
the  PIAS (protein inhibitor of activated STAT) 
family, RanBP2 (Ran-binding protein 2) and Pc2 
(Polycomb 2) have been identified as SUMO E3 
ligases (3-5). Sumoylation is a highly dynamic 
and reversible modification with substrates 
undergoing rapid conjugation and de-
conjugation. The removal of SUMO is catalysed 
by SUMO-specific isopeptidases of SENPs/ 
SUSP family (2,6). Despite the similarity 
between sumoylation and ubiquitination 
pathway, the functional consequences of these 
two modifications are quite different. Unlike 
ubiquitination which primarily facilitates the 
target protein for degradation, sumoylation has 
diverse effects including regulation of protein-
protein interactions, sub-cellular localization, 
protein stability, and alteration of transcriptional 
activity of substrate proteins. Transcription 
factors are the largest group of target proteins 
whose functions are modified by sumoylation, 
and in most studies reported, sumoylation poses 
a negative effect on the activities of transcription 
factors (7-9). 
Sharp-1 is a basic helix-loop-helix 
(bHLH)-Orange domain containing 
transcriptional repressor that is expressed in 
many cell types during embryonic development 
as well as in adult tissues (10-14). Sharp-1 binds 
to class B E-Box sites CACGTG with high 
affinity to repress transcription of target genes 
(15,16). Unlike related Hey and Hes sub-family 
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members which recruit the co-repressor 
transducin-like enhancer of split (TLE)/Groucho 
through a WRPW motif, Sharp-1 lacks the 
WRPW motif and associates with distinct co-
repressors including histone deacetylase 1 
(HDAC1) and the lysine methyltransferase G9a 
(12,17).  
The myogenic regulatory factor MyoD 
plays a central role in differentiation of skeletal 
muscle precursor cells. MyoD heterodimerizes 
with ubiquitously expressed E proteins and binds 
to E-box sequences (CANNTG) present in 
promoters of muscle genes to turn on their 
expression. Sharp-1 expression is modulated 
during myogenesis, being high in 
undifferentiated cells and declines during 
differentiation. Both gain of function and loss of 
function studies have shown that Sharp-1 
impairs myogenic differentiation through 
antagonism of MyoD (10,17). The mechanisms 
underlying Sharp-1 dependent inhibition of 
differentiation include dimerization with MyoD 
and E proteins. In addition, we have recently 
shown that Sharp-1 interacts with G9a, a lysine 
methyltransferase that mediates repressive 
histone H3 lysine 9 di-methylation (H3K9me2) 
marks and recruits it to MyoD target promoters. 
Consistent with the recruitment of G9a,  
enrichment in H3K9me2 is apparent at MyoD 
target promoters in Sharp-1 overexpressing cells. 
Moreover, MyoD methylation at lysine 104 
(K104) is also enhanced by G9a (10,18). Thus 
inhibition of G9a expression or activity partially 
rescues Sharp-1-dependent repression of 
myogenesis (17). While these studies have 
implicated G9a as a mediator of Sharp-1-
dependent inhibition of myogenesis, the 
molecular mechanisms that regulate its 
recruitment by Sharp-1 are unclear.  
In this study, we provide evidence that 
SUMO modification of Sharp-1 serves as a 
platform for recruitment of the co-repressor G9a, 
and its ability to inhibit myogenesis. We 
demonstrate that Sharp-1 is sumoylated at two 
highly conserved lysine residues K240 and K255, 
which is further enhanced by PIAS3 and 
PIASxα.  Mutation of these lysine acceptor sites 
in Sharp-1 (Sharp-1 2KR) abolishes sumoylation 
without any impact on its sub-cellular 
localization. However, in contrast to wild type 
Sharp-1 which inhibits MyoD transcriptional 
activity and myogenic differentiation, the 
sumoylation defective mutant Sharp-1 2KR is 
significantly less efficient at blocking MyoD and 
myogenesis. Interestingly, unlike wild type 
Sharp-1, Sharp-1 2KR exhibits a markedly 
reduced association with G9a, and is insensitive 
to inhibitors of G9a activity.  Taken together, 
these studies reveal a key role for SUMO 
modification of Sharp-1 in the recruitment of 
G9a and inhibition of myogenic differentiation.  
Experimental Procedures 
Cell culture and differentiation assays. C2C12 
cells were cultured and maintained in growth 
medium (GM) consisting of Dulbecco's 
modified Eagle's medium (DMEM) with 20% 
fetal bovine serum (FBS; Hyclone). HEK293 
and C3H10T1/2 (10T1/2) cells were maintained 
in DMEM supplemented with 10% FBS (Gibco), 
and COS-7 cells in DMEM with 10% calf serum 
(Hyclone).  
C2C12 cells were co-transfected with a 1:9 ratio 
of an expression vector for pCS2, Sharp-1 or 
Sharp-1 2KR and pBabe (which confers 
resistance to puromycin). To test the role of 
sumoylation, SENP1 was transfected as 
indicated. 48 h after transfection, cells were 
selected in medium containing 2 µg/ml 
puromycin for two days. Selected cells were 
differentiated in differentiation medium (DM), 
consisting of DMEM plus 2% horse serum 
(Hyclone). For myogenic conversion assays, 
10T1/2 cells were transfected with equivalent 
levels of MyoD alone, or with Sharp-1 or Sharp-
1 2KR. Undifferentiated (Day 0) and 
differentiated cells (Day 6) were harvested for 
analysis of protein lysates by western blot, and 
fixed for immunofluorescence assays. To 
quantify differentiation, myogenic index was 
calculated as the ratio of nuclei in MHC+ 
myotubes/total nuclei across 4 different 
microscopic fields. 700-1000 nuclei were 
counted. 
Immunofluorescence assays: For 
differentiation assays, cells were washed with 
PBS and fixed in ice cold 4% paraformaldehyde. 
After permeabilization, cells were incubated 
with anti-MHC (MY32) (Sigma) antibody and 
detected with secondary antibody coupled with 
Alexa Fluor (Molecular Probes). Slides were 
mounted in Vectashield mounting medium 
(Vector laboratories) containing DAPI (4′, 6′-
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diamidino-2-phenylindole) to stain nuclei. 
Images were captured using a Nikon Eclipse TE 
2000-U fluorescence microscope using 
MetaMorph software (version 7.0r3).   COS-7 
cells were used to examine subcellular 
localization of Myc-tagged Sharp-1 and Sharp-1 
2KR. Cells were seeded at a density of 1x104 
cells/well in 6-well plates. 24 h later, cells were 
transfected with Myc-Sharp-1 and Myc-Sharp-1 
2KR, or additionally co-transfected  with 
SUMO-1. 48 h after transfection, cells were 
fixed, incubated with mouse anti-Myc antibody 
and detected with Texas-red (Invitrogen) 
coupled secondary antibody. Cells were 
visualized on a Zeiss LSM 510 META confocal 
laser-scanning microscope.  
Plasmids and mutagenesis: Flag-mPIAS1, 
Flag-mPIAS3 Flag-mPIASxα, Flag-mPIASy, 
SUMO-1, SENP1 were kindly provided by 
Martin Lee (19). pCS2-Myc-Sharp-1 has been  
described (17). To mutate potential sumoylation 
residues from lysine (K) to arginine (R) in 
Sharp-1, QuickChangeTM site-directed 
mutagenesis kit (Stratagene) was used. The 
primers for generating pCS2-Myc-Sharp-1 
K240R   are: 5’-CGC GCG GCC GTC CGA 
CAG GAG CCA CCC-3’ and 5’-GGG TGG 
CTC CTG TCG GAC GGC CGC GCG-3’; 
primers for Sharp-1 2KR are: 5’-CCC AAG 
AGG CCG CGA CTG GAG GCG CGC-3’ and 
5’-GCG CGC CTC CAG TCG CGG CCT CTT 
GGG-3’. The cDNA was sequenced entirely to 
confirm the presence of directed mutations. 
Immunoprecipitation and western blotting: 
To detect sumoylation, expression vectors were 
transfected using LipofectamineTM2000 as 
described (20). Cells were collected 48 h after 
transfection and lysed in presence of 20 mM 
NEM (N-ethylmaleimide (Sigma) using an ice-
cold lysis buffer (50mM Tris-HCl pH 8.0, 50 
mM  NaCl, 1 mM EDTA, 0.1% Triton X-100, 
0.5 mM PMSF and protease inhibitors (Roche). 
Lysates were analyzed by western blotting using 
the following antibodies: anti-SUMO-1, anti-
Myc, anti-Flag and anti-β-actin. For co-
immunoprecipitation assays, Myc-tagged Sharp-
1 and Sharp-1 2KR were transfected into C2C12 
cells. Lysates were immunoprecipitated using 
Myc-agarose beads and analyzed for association 
with endogenous MyoD by western blotting 
using anti-MyoD (Santa Cruz) or endogenous 
G9a using anti-G9a antibody (Cell Signaling).  
Chromatin Immunoprecipitation assays 
(ChIP): C2C12 cells were transfected with 
vector alone, Sharp-1 or Sharp-1 2KR, and 
SENP-1. ChIP assays were performed using a kit 
as described by the manufacturer (Upstate)  with 
2 µg H3K9me2 antibody (Millipore), 10µl of 
G9a antibody (Abcam), 2 µg anti-Sharp-1 
antibody (Santa Cruz). DNA was amplified with 
primers specific to myogenin promoter as 
described previously (17). 
Luciferase assays: HEK293T cells were 
transfected with 9E-TK-luc reporter along with 
Sharp-1 or Sharp-1 2KR. 10T1/2 cells were 
transfected with pMyogLuc promoter reporter, 
MyoD, Sharp-1 and Sharp-1 2KR as indicated in 
the figures together with 5 ng of Renilla 
luciferase. 24 h after transfection, UNC0638 
(Sigma) was added for 24 h, after which cells 
were lysed and assayed using the dual-luciferase 
reporter assay system (Promega). Each 
transfection was performed in triplicates, and 
repeated at least twice. Values were reported as 
means with standard deviation (shown as error 
bars).  
Statistical analysis: Error bars indicate mean ± 
standard deviation (S.D.). Statistical analysis 
was performed using Student’s t-test 
and  p values <0.05 were considered statistically 
significant.  
Results     
Sharp-1 is SUMO modified 
We have recently reported that Sharp-1 
interacts with the co-repressor G9a to inhibit 
differentiation of skeletal muscle precursor cells 
(17). The interaction mapped to amino acid 
residues 173-265 in Sharp-1. Further 
examination of this region revealed two highly 
conserved lysine residues that perfectly matched 
the consensus sumoylation motif: lysine (K) 240 
in the sumoylation motif VKQE; and K255 in 
the sequence PKLE (Fig. 1A). To determine 
whether Sharp-1 undergoes sumoylation, we 
transiently co-transfected HEK293 cells with 
Myc-Sharp-1 and SUMO-1. Cells were lysed in 
the presence of N-ethylmaleimide (NEM), an 
inhibitor of SUMO hydrolases, and lysates were 
immunoprecipitated with Myc-agarose beads 
followed by western blotting with anti-SUMO-1 
antibody. Interestingly, in the presence of 
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SUMO-1, Sharp-1 appeared to be sumoylated 
(Fig. 1B).  Furthermore, in presence of co-
transfected SENP1 (Sentrin-specific protease1), 
which is able to remove SUMO conjugates from 
target proteins, Sharp-1 sumoylation was almost 
abolished.  These results confirmed that Sharp-1 
is SUMO conjugated in cells.  
To validate that K240 and K255 are 
bonafide sumoylation sites, we generated point 
mutants changing the putative target lysine 
residues to arginine with site-directed 
mutagenesis. These mutants as well as wild type 
Sharp-1 were co-expressed with SUMO-1 in 
cells. Immunoprecipitation and western blotting 
analysis revealed that mutation of K240 alone 
(K240R), or both K240 and K255 (2KR) to 
arginine abrogated sumoylation even in the 
presence of SUMO-1 indicating  that K240 is the 
major site for SUMO modification of Sharp-1 
(Fig. 1C). 
Most sumoylation reactions are 
enhanced by specific SUMO E3 ligases, of 
which the PIAS family proteins have been well-
characterized (5). To determine whether PIAS 
proteins regulate Sharp-1 sumoylation,  we co-
transfected cells with Myc-Sharp-1, SUMO-1 
and Flag-PIAS1, PIAS3, PIASxα, and PIASy. 
Cell lysates were immunoprecipitated with Myc-
agarose beads, followed by western blotting with 
anti-SUMO-1 antibody. Overexpression of 
PIAS3 and PIASxα enhanced sumoylation of 
Sharp-1, whereas the presence of PIAS1 and 
PIASy had a minimal impact, suggesting that 
PIAS3 and PIASxα act as E3 SUMO ligases for 
Sharp-1 (Fig. 1D). To examine whether 
sumoylation of Sharp-1 is physiologically 
relevant in myogenesis, we first sought to 
determine whether Sharp-1 is SUMO conjugated 
in muscle cells. C2C12 myoblasts were co-
transfected with Myc-Sharp-1 and SUMO-1. 
Cell lysates from undifferentiated cells and 24 h 
after induction of differentiation were 
immunoprecipitated with Myc-agarose beads 
followed by western blotting with anti-SUMO-1 
antibody. Sumoylation of Sharp-1 was detected 
in undifferentiated C2C12 cells, and was 
significantly reduced upon differentiation (Fig. 
1E). To further validate this finding, endogenous 
Sharp-1 was immunoprecipitated from 
undifferentiated and differentiated C2C12 cells. 
Consistent with the previous results, endogenous 
Sharp-1 was SUMO conjugated to higher levels 
in undifferentiated cells compared to 
differentiated cells (Fig. 1F).  
Sub-cellular localization of Sharp-1 is not 
altered by SUMO modification 
Since sumoylation has been shown to 
affect sub-cellular distribution of a number of 
target proteins, we analyzed localization of 
Sharp-1 and Sharp-1 2KR. Cells were 
transfected with Myc-Sharp-1 or Myc-Sharp-1 
2KR in the absence and presence of SUMO-1, 
and visualized by confocal microscopy. Both 
proteins showed almost identical patterns of 
localization (Fig. 2A), suggesting that the 
nuclear localization of Sharp-1 is independent of 
its sumoylation status. To test the impact of 
sumoylation in Sharp-1 mediated transcriptional 
repression, cells were transfected with 9E-TK-
Luc, a reporter harbouring Sharp-1 binding sites 
(21) . Consistent with previous reports (17), 
overexpression of wild type Sharp-1 
significantly repressed reporter activity. In 
contrast, Sharp-1 2KR was considerably less 
potent in mediating transcriptional repression of 
the reporter (Fig. 2B).    
Sumoylation of Sharp-1 is required to inhibit 
myogenic differentiation   
We have previously found that Sharp-1 
inhibits the differentiation of skeletal muscle 
precursor cells (10,17). To investigate the 
biological relevance of Sharp-1 sumoylation, we 
tested the possibility that sumoylation is 
involved in this process. C2C12 cells were co-
transfected with Myc-tagged Sharp-1, Sharp-1 
2KR together with the puromycin resistance 
vector pBabe. Both Sharp-1 and Sharp-1 2KR 
were expressed at similar levels (Fig. 3A). After 
selection, cells were analyzed for their ability to 
differentiate relative to control vector expressing 
cells. Consistent with our previous reports (10, 
17), overexpression of Sharp-1 resulted in 
significant inhibition in myogenic differentiation 
as evidenced by a reduced number of terminally 
differentiated cells expressing myosin heavy 
chain (MHC) compared with vector-transfected 
cells (Fig. 3B, C). Interestingly, in contrast to 
wild type Sharp-1, the SUMO-defective mutant 
Sharp-1 2KR did not inhibit differentiation as 
efficiently as Sharp-1 (Fig. 3B, C). To confirm 
this finding, the expression of Troponin T, a 
differentiation marker was examined. 
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Consistently, Troponin T levels were reduced in 
Sharp-1 expressing cells, while Sharp-1 2KR 
expressing cells did not show a significant 
change in the expression of this marker at late 
stages of differentiation (Fig. 3D).  
To further confirm that Sharp-1-
mediated muscle differentiation inhibition is 
SUMO-dependent, we investigated whether de-
sumoylation of Sharp-1 resulted in a phenotype 
similar to Sharp-1 2KR expressing cells. The 
SUMO protease SENP1 was co-transfected with 
equivalent levels of Sharp-1 and Sharp-1 2KR in 
C2C12 cells (Fig. 4A). Consistent with a role for 
sumoylation, inhibition of myogenesis by Sharp-
1 was partially reversed with the addition of 
SENP1 (Fig. 4B, C). On the other hand, 
expression of SENP1 had no impact on Sharp-1 
2KR. We then investigated the molecular 
mechanisms underlying the differential impact 
on differentiation between Sharp-1 and Sharp-1 
2KR. We have recently demonstrated that 
Sharp-1 recruits G9a, and correspondingly 
H3K9me2, is enhanced in Sharp-1 
overexpressing cells (17). We therefore analyzed 
H3K9me2 in cells expressing Sharp-1 and 
Sharp-1 2KR. Consistent with our recent report, 
H3K9me2 was enriched in C2C12 cells 
expressing Sharp-1 compared to control cells. 
Interestingly however, no enrichment was 
observed in cells expressing equivalent levels of 
Sharp-1 2KR and Sharp-1 co-transfected with 
SENP1 (Fig. 4D). Corresponding with 
enrichment of H3K9me2 marks, G9a occupancy 
was higher in Sharp-1 overexpressing cells 
relative to Sharp-1 2KR cells. However, no 
significant differences were apparent in Sharp-1 
recruitment between the two cells lines (Fig. 
4E,F).  Together, these results demonstrate that 
sumoylation of Sharp-1 is important for its 
ability to inhibit myogenic differentiation and 
for enrichment of G9a-dependent H3K9me2 
marks at the myogenin promoter. These results 
also suggest that sumoylation may be important 
for recruitment of G9a.  
Sharp-1 sumoylation is essential for 
suppression of MyoD transcriptional activity 
and function 
Since our previous studies have shown 
that Sharp-1 inhibits MyoD function (17), we 
examined the impact of Sharp-1 sumoylation 
specifically on MyoD transcriptional activity 
and MyoD-dependent myogenic conversion. 
10T1/2 cells were transfected with MyoD alone, 
or with equivalent amount of Sharp-1 and Sharp-
1 2KR (Fig. 5A). MyoD dependent myogenic 
conversion was inhibited in cells expressing 
MyoD and Sharp-1. On the other hand, Sharp-1 
2KR expressing cells differentiated better and 
exhibited a higher percentage of MHC+ cells 
(Fig. 5B) and increased myogenic index (Fig. 
5C), indicating that Sharp-1 2KR was less potent 
in the repression of MyoD function. Consistent 
with the effect on myogenic differentiation, 
Troponin T expression was reduced to a greater 
extent in Sharp-1 overexpressing cells relative to 
control cells but no such reduction was seen in  
cells expressing Sharp-1 2KR (Fig. 5D). We 
then tested the impact of Sharp-1 sumoylation 
on MyoD transcriptional activity which is 
inhibited by Sharp-1 (10,18). 10T1/2 cells were 
transfected with the myogenin promoter reporter 
pMyog-Luc (22)  along with MyoD alone, or 
together with Sharp-1 or Sharp-1 2KR. Cell 
extracts were analyzed for luciferase activity. As 
reported previously, Sharp-1 significantly 
repressed the myogenin promoter, whereas the 
2KR mutant was less effective in repression (Fig. 
5E). To examine whether reduced transcriptional 
repression by Sharp-1 2KR may be a 
consequence of impaired association with MyoD, 
we examined interaction of wild type and 
sumoylation defective Sharp-1 with endogenous 
MyoD. C2C12 were transfected with equivalent 
levels of Myc-tagged Sharp-1 and Sharp-1 2KR. 
Lysates were immunoprecipitated and examined 
for association with MyoD (Fig. 5F). Consistent 
with our previous reports Sharp-1 interacted 
with MyoD (10), and no significant difference 
was apparent in the ability of Sharp-1 2KR to 
interact with MyoD. These data indicate that 
sumoylation is not involved in the association of 
Sharp-1 and MyoD, and support the notion that 
sumoylation impacts Sharp-1 dependent 
transcriptional repression.  
SUMO modification of Sharp-1 is essential 
for its interaction with G9a 
We have recently demonstrated that 
Sharp-1 interacts with the co-repressor G9a 
through the region spanning the sumoylation 
motifs (17). Several reports suggest that protein-
protein interactions are SUMO modification-
dependent. A SUMO Binding Motif (SBM) 
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consensus sequence V/I-X-V/I-V/I present in 
many proteins is known to be important for their 
recruitment by SUMO modified transcription 
factors (23).  To investigate the mechanisms that 
render non-SUMO modified Sharp-1 a less 
efficient suppressor of myogenesis, we 
examined the cDNA sequence of G9a. 
Interestingly, we identified a SBM consensus 
ID/EVI which is conserved in G9a from various 
species (Fig. 6A). Moreover, G9a SBM is within 
its ANK repeats sequence which is essential for 
G9a interaction with Sharp-1 (17). To examine if 
SUMO modification of Sharp-1 is essential for 
its interaction with G9a, co-immunoprecipitation 
assays were performed. 293 cells were co-
transfected with Flag-G9a, Myc-Sharp-1 and 
Myc-Sharp-1 2KR. Consistent with previous 
studies (17), immunoprecipitation of Sharp-1 
revealed its association with G9a (Fig. 6B).  
Interestingly, the association of Sharp-1 2KR 
with G9a was greatly reduced. To validate these 
findings in muscle cells, we examined the 
interaction of Sharp-1 and Sharp-1 2KR with 
endogenous G9a in C2C12 cells. Similar to the 
impact seen in 293 cells, Sharp-1 2KR exhibited 
reduced interaction with endogenous G9a in 
C2C12 cells compared to wild type Sharp-1 (Fig. 
6C). To corroborate the findings that 
sumoylation regulates the interaction between 
G9a and Sharp-1, we examined the impact of 
SENP1 on the association of Sharp-1 with G9a. 
Consistent with the reduced interaction of G9a 
with Sharp-1 2KR, expression of SENP1 
reduced association of wild type Sharp-1 and 
G9a (Fig. 6D). We then tested whether 
inhibition of G9a impacts SUMO-dependent 
transcriptional repression mediated by Sharp-1. 
To address this, the myogenin promoter reporter 
pMyog-Luc was transfected in 10T1/2 cells 
along with MyoD, Sharp-1 and Sharp-1 2KR. 24 
h later, 0.25 µM UNC0638, a pharmacological 
inhibitor of G9a methyltransferase activity, was 
added. In presence of UNC0638, transcriptional 
repression mediated by Sharp-1 was reversed. 
On the other hand, Sharp-1 2KR-mediated 
repression was not significantly impacted by 
UNC0638 (Fig. 6E). Taken together, these 
results demonstrate that recruitment of G9a is 
sumoylation dependent and impacts the ability 
of Sharp-1 to mediate transcriptional repression 
of MyoD transcriptional activity and myogenic 
differentiation.  
Discussion 
In this study, we report that Sharp-1 
undergoes SUMO-1 dependent sumoylation at 
conserved lysine residues K240 and K255. The 
E3 SUMO ligases PIAS3 and PIASxα enhance 
Sharp-1 sumoylation. Mutation of the SUMO 
acceptor lysine residues does not impact the sub-
cellular localization of Sharp-1; however it does 
attenuate its transcriptional repression capacity, 
abrogate interaction with the chromatin modifier 
G9a, and impacts its function as a repressor of 
myogenic differentiation.    
Like other members of the bHLH-O 
subfamily, Sharp-1 is a potent transcriptional 
repressor (10,12,17). However, the mechanisms 
underlying transcriptional regulation by Sharp-1 
remain unclear. Our previous studies linked the 
transcriptional repression activity of Sharp-1 to 
its role as an inhibitor of cellular differentiation 
along the skeletal muscle as well as the 
adipocytic lineage (10,17,24). The 
transcriptional repression of myogenic 
differentiation by Sharp-1 relies on inhibition of 
MyoD transcriptional activity. This is achieved, 
in part, through dimerization with MyoD and E-
proteins.  In addition, Sharp-1 recruits the co-
repressor G9a through a C-terminal region 
spanning amino acid residues 173-265. In 
support of this, disruption of the interaction with 
G9a results in reduced transcriptional repression 
of MyoD by Sharp-1.  Moreover, overexpression 
of Sharp-1 results in enrichment of H3K9me2 
marks that are mediated by G9a at MyoD target 
promoters. Conversely, loss of G9a expression 
or activity attenuates the ability of Sharp-1 to 
repress myogenic differentiation with a 
concomitant reduction of H3K9me2 occupancy. 
Collectively, these data demonstrate that G9a 
mediates transcriptional repression and 
inhibition of myogenesis by Sharp-1.     
Sumoylation plays an important role in 
the regulation of transcription factor activity and 
function which includes an impact on protein 
stability, cellular localization, DNA-binding, and 
protein-protein interactions. An emerging theme 
among these is the role of sumoylation in 
transcriptional repression by facilitating 
assembly of complexes that regulate chromatin 
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accessibility and gene expression. Consistent 
with this notion, SUMO modification at K240 
and K255 in Sharp-1 is essential for its full 
transcriptional repression activity.  This is 
evidenced by the attenuated ability of the SUMO 
defective mutant Sharp-1 2KR in mediating 
repression of MyoD transcriptional activity and 
MyoD-dependent myogenic conversion of 
fibroblast cells compared to wild type Sharp-1. 
Similarly, co-expression of SENP1 with wild 
type Sharp-1 mimics the phenotype of Sharp-1 
2KR cells. Interestingly, sumoylation of Sharp-1 
at K240 and K255 creates an interface for 
recruitment of G9a, and possibly assembly of 
other chromatin modifiers/remodelling 
complexes. Thus loss of Sharp-1 sumoylation 
correlates with reduced G9a dependent 
H3K9me2 marks and repression of muscle 
promoters. These findings are in line with other 
reports that have demonstrated a link between 
SUMO modification of transcription factors and 
transcriptional repression via recruitment of co-
repressors. Several studies have linked 
sumoylation with HDACs. For instance, SBM 
containing HDAC6 and HDAC2 are recruited by 
sumoylated p300 and Elk-1 respectively to target 
promoters to repress transcription (25, 26). 
Similarly, sumoylation of Stra13, a bHLH factor 
related to Sharp-1 facilitates interaction with 
HDAC1 (20). In addition to G9a, a previous 
study has demonstrated that Sharp-1 also 
interacts with HDAC1 and Sirt1 (12). However, 
in the case of Sharp-1, the interaction with 
HDAC1 and Sirt1 maps to a different region that 
include the C-terminus encompassing amino 
acids 265-410 for HDAC1, and the bHLH 
domain for Sirt1. Thus, the association and 
recruitment of HDAC1 and Sirt1 is not likely to 
be dependent on sumoylation of Sharp-1. 
 While many studies have shown the role 
of sumoylation in regulation of transcription 
factor activity, the role of sumoylation in control 
of cellular differentiation is largely unclear. 
During myogenic differentiation, the overall 
levels of SUMO modified proteins decline (27). 
While a few transcription factors such as the 
homeoprotein Msx1 and Myocyte enhancer 
factor (MEF2) are known to be sumoylated, the 
role of SUMO modification of these 
transcription factors in regulation of muscle gene 
expression is unclear. For instance, Msx1 is 
SUMO modified, and was recently shown to 
repress myogenesis by recruiting G9a (28,29). 
However the functional relevance of SUMO 
modification of Msx1 in recruitment of G9a, or 
in the control of myogenesis has not been 
reported. Similarly, the MEF2 transcription 
factors which play a key role during myogenesis 
by activating muscle specific genes are also 
known to be sumoylated.  MEF2A is modified 
by SUMO-1, and MEF2C and MEF2D are 
modified by SUMO-2 and SUMO-3 (30,31). 
Sumoylation of MEF2 proteins represses their 
transcriptional activity, but whether it impacts 
their function in myogenesis remains to be 
clarified. A recent study demonstrated that Pax7 
is SUMO modified, and sumoylation at K85 is 
important for Pax7 mediated repression of 
myogenesis and transactivation of selective 
target genes (32). However, the mechanisms by 
which sumoylation of Pax7 regulates its 
transcriptional activity remain to be investigated. 
In this regard, our findings identify a novel 
regulatory axis that links sumoylation to the 
control of skeletal muscle differentiation by 
regulation of G9a recruitment and consequently 
the transcriptional repression activity of  Sharp-1. 
Acknowledgements 
We thank MBH Lee, G. Pavlath, M. Rossner, 
and M Walsh for various plasmid constructs.  
This research is supported by the Singapore 
Ministry of Health’s National Medical Research 




	   9	  
References 
1. Muller, S., Ledl, A., and Schmidt, D. (2004) SUMO: a regulator of gene expression and genome 
integrity. Oncogene 23, 1998-2008 
2. Gill, G. (2003) Post-translational modification by the small ubiquitin-related modifier SUMO has 
big effects on transcription factor activity. Current Opinion in Genetics & Development 13, 108-
113 
3. Melchior, F. (2000) SUMO--nonclassical ubiquitin. Annual Review of Cell and Developmental 
Biology 16, 591-626 
4. Geiss-Friedlander, R., and Melchior, F. (2007) Concepts in sumoylation: a decade on. Nature 
reviews. Molecular Cell Biology 8, 947-956 
5. Kotaja, N., Karvonen, U., Janne, O. A., and Palvimo, J. J. (2002) PIAS proteins modulate 
transcription factors by functioning as SUMO-1 ligases. Molecular and Cellular Biology 22, 
5222-5234 
6. Malakhov, M. P., Mattern, M. R., Malakhova, O. A., Drinker, M., Weeks, S. D., and Butt, T. R. 
(2004) SUMO fusions and SUMO-specific protease for efficient expression and purification of 
proteins. Journal of Structural and Functional Genomics 5, 75-86 
7. Gill, G. (2005) Something about SUMO inhibits transcription. Current Opinion in Genetics & 
Development 15, 536-541 
8. Girdwood, D. W., Tatham, M. H., and Hay, R. T. (2004) SUMO and transcriptional regulation. 
Seminars in Cell & Developmental Biology 15, 201-210 
9. Johnson, E. S. (2004) Protein modification by SUMO. Annual Review of Biochemistry 73, 355-
382 
10. Azmi, S., Ozog, A., and Taneja, R. (2004) Sharp-1/DEC2 inhibits skeletal muscle differentiation 
through repression of myogenic transcription factors. The Journal of Biological Chemistry 279, 
52643-52652 
11. Azmi, S., and Taneja, R. (2002) Embryonic expression of mSharp-1/mDEC2, which encodes a 
basic helix-loop-helix transcription factor. Mech Develop 114, 181-185 
12. Fujimoto, K., Hamaguchi, H., Hashiba, T., Nakamura, T., Kawamoto, T., Sato, F., Noshiro, M., 
Bhawal, U. K., Suardita, K., and Kato, Y. (2007) Transcriptional repression by the basic helix-
loop-helix protein Dec2: multiple mechanisms through E-box elements. International Journal of 
Molecular Medicine 19, 925-932 
13. Fujimoto, K., Shen, M., Noshiro, M., Matsubara, K., Shingu, S., Honda, K., Yoshida, E., Suardita, 
K., Matsuda, Y., and Kato, Y. (2001) Molecular cloning and characterization of DEC2, a new 
member of basic helix-loop-helix proteins. Biochemical and Biophysical Research 
Communications 280, 164-171 
14. Li, Y., Zhang, H., Xie, M., Hu, M., Ge, S., Yang, D., Wan, Y., and Yan, B. (2002) Abundant 
expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-
induced apoptosis and selective inhibition of procaspase activation. The Biochemical Journal 367, 
413-422 
15. Azmi, S., Sun, H., Ozog, A., and Taneja, R. (2003) mSharp-1/DEC2, a basic helix-loop-helix 
protein functions as a transcriptional repressor of E box activity and Stra13 expression. The 
Journal of Biological Chemistry 278, 20098-20109 
16. Sun, H., Ghaffari, S., and Taneja, R. (2007) bHLH-Orange Transcription Factors in Development 
and Cancer. Translational Oncogenomics 2, 107-120 
17. Ling, B. M., Gopinadhan, S., Kok, W. K., Shankar, S. R., Gopal, P., Bharathy, N., Wang, Y., and 
Taneja, R. (2012) G9a mediates Sharp-1-dependent inhibition of skeletal muscle differentiation. 
Molecular Biology of the Cell 23, 4778-4785 
18. Ling, B. M., Bharathy, N., Chung, T. K., Kok, W. K., Li, S., Tan, Y. H., Rao, V. K., Gopinadhan, 
S., Sartorelli, V., Walsh, M. J., and Taneja, R. (2012) Lysine methyltransferase G9a methylates 
	   10	  
the transcription factor MyoD and regulates skeletal muscle differentiation. Proceedings of the 
National Academy of Sciences of the United States of America 109, 841-846 
19. Lee, M. B., Lebedeva, L. A., Suzawa, M., Wadekar, S. A., Desclozeaux, M., and Ingraham, H. A. 
(2005) The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor 
activity via SUMO modification. Molecular and Cellular Biology 25, 1879-1890 
20. Wang, Y., Rao, V. K., Kok, W. K., Roy, D. N., Sethi, S., Ling, B. M., Lee, M. B., and Taneja, R. 
(2012) SUMO modification of Stra13 is required for repression of cyclin D1 expression and 
cellular growth arrest. PloS One 7, e43137 
21. Rossner, M. J., Oster, H., Wichert, S. P., Reinecke, L., Wehr, M. C., Reinecke, J., Eichele, G., 
Taneja, R., and Nave, K. A. (2008) Disturbed clockwork resetting in Sharp-1 and Sharp-2 single 
and double mutant mice. PloS One 3, e2762 
22. Friday, B. B., Horsley, V., and Pavlath, G. K. (2000) Calcineurin activity is required for the 
initiation of skeletal muscle differentiation. The Journal of Cell Biology 149, 657-666	  	  
23. Song, J., Durrin, L. K., Wilkinson, T. A., Krontiris, T. G., and Chen, Y. (2004) Identification of a 
SUMO-binding motif that recognizes SUMO-modified proteins. Proceedings of the National 
Academy of Sciences of the United States of America 101, 14373-14378 
24.	   Gulbagci NT, Li L, Ling B, Gopinadhan S, Walsh M, Rossner M, Nave KA, Taneja R. (2009) 
SHARP1/DEC2 inhibits adipogenic differentiation by regulating the activity of C/EBP. EMBO 
Rep. 10, 79-86 
25. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, 
Perkins ND, Hay RT. (2003)  P300 transcriptional repression is mediated by SUMO modification. 
Mol Cell. 11, 1043-54  
26. Yang SH, Sharrocks AD. (2004) SUMO promotes HDAC-mediated transcriptional repression. 
Mol Cell 13, 611-7 
27. Riquelme, C., Barthel, K. K., Qin, X. F., and Liu, X. (2006) Ubc9 expression is essential for 
myotube formation in C2C12. Experimental Cell Research 312, 2132-2141 
28. Gupta, V., and Bei, M. (2006) Modification of Msx1 by SUMO-1. Biochemical and Biophysical 
Research Communications 345, 74-77 
29. Wang, J., and Abate-Shen, C. (2012) The MSX1 homeoprotein recruits G9a methyltransferase to 
repressed target genes in myoblast cells. PloS One 7, e37647 
30. Gregoire, S., and Yang, X. J. (2005) Association with class IIa histone deacetylases upregulates 
the sumoylation of MEF2 transcription factors. Molecular and Cellular Biology 25, 2273-2287 
31. Riquelme, C., Barthel, K. K., and Liu, X. (2006) SUMO-1 modification of MEF2A regulates its 
transcriptional activity. Journal of Cellular and Molecular Medicine 10, 132-144 
32. Luan Z, Liu Y, Stuhlmiller TJ, Marquez J, García-Castro MI. (2012) SUMOylation of Pax7 is 
essential for neural crest and muscle development. Cell Mol Life Sci.  70, 1793-806 
 
  





Figure 1. Sharp-1 is SUMO modified. A, The domain structure Sharp-1 is shown with the basic, helix-
loop-helix (HLH), and the Orange domains (upper panel). Potential sumoylation sites at K240 and K255 
are indicated. Alignment of the two SUMO consensus motifs in Sharp-1 cDNA from human, mouse, rat, 
dog and xenopus showed high conservation across species. B, Cells were co-transfected with constructs 
encoding Myc-Sharp-1, SUMO-1 and SENP1 as indicated. Lysates were subjected to 
immunoprecipitation with Myc-agarose beads followed by immunoblotting with anti-SUMO-1 antibody. 
Anti-Myc antibody was used to detect expression of Sharp-1. β-actin served as a loading control. C, Cells 
were co-transfected with Myc-Sharp-1, Sharp-1 K240R, and Sharp-1 2KR along with SUMO-1. Lysates 
were immunoprecipitated with Myc-agarose beads followed by western blotting with anti-SUMO-1 
antibody. D, Flag-tagged PIAS1, PIAS3, PIASxa and PIASy were co-transfected with Myc-Sharp-1 and 
SUMO-1. Cell lysates were immunoprecipitated with Myc-agarose beads and immunoprecipitates were 
subjected to western blotting with anti-SUMO-1 antibody. Sharp-1 and PIAS proteins were detected with 
anti-Myc and anti-Flag antibodies respectively. E, C2C12 cells were co-transfected with Myc-Sharp-1 
and SUMO-1. Cells were harvested as undifferentiated cells (D0) and one day after differentiation (D1), 
immunoprecipitated with Myc-agarose beads followed by western blotting with anti-SUMO-1 and anti-
Myc antibodies. F, C2C12 cells were transfected with SUMO-1. Endogenous Sharp-1was 
immunoprecipitated from D0 and D1 lysates using anti-DEC2 (Sharp-1) antibody followed by western 
blotting with anti-SUMO-1 antibody. 
Figure 2.  Sumoylation impacts Sharp-1 mediated transcriptional repression but not its sub-cellular 
localization. A, COS-7 cells were transfected with Sharp-1 and Sharp-1 2KR alone or together with 
SUMO-1. 48 h later, cells were fixed and stained with anti-Myc antibody. DAPI was  used to stain and 
visualize nuclei. B, 293T cells were transfected with 9E-TK-Luc reporter (100ng) along with Sharp-1 
(50ng) or Sharp-1 2KR (50ng) as indicated. 48 h later, cells were harvested and luciferase activity was 
measured. Error bars indicate mean±SD. 
 
Figure 3. Mutation of sumoylation sites abrogates the ability of Sharp-1 to suppress myogenesis. A, 
C2C12 cells were co-transfected with Sharp-1 or Sharp-1 2KR along with a puromycin resistance vector. 
Empty vector (pCS2) was transfected in control cells. Sharp-1 and Sharp-1 2KR expression was 
determined by western blotting with anti-Myc antibody. B-C, MHC staining (B) and myogenic index (C) 
was assessed in Sharp-1 and 2KR expressing cells compared to control cells at Day 2 of differentiation. D, 
Cell lysates at Day 0, 1 and 2 of differentiation from control, Sharp-1 and Sharp-1 2KR cells were 
analyzed by western blotting using Troponin T antibody. Error bars indicate mean±SD. 
 
Figure 4. SENP1 rescues Sharp-1 mediated suppression of myogenesis. A, C2C12 cells were 
transfected with vector alone (Control), Myc-Sharp-1, or Sharp-1 2KR individually or together with 
SENP1. Lysates  were immunoblotted with anti-Myc antibody. B-C, After selection, differentiation was 
analyzed at Day 2 with anti-MHC antibody. Nuclei were stained with DAPI (B). Myogenic index was 
determined. D, ChIP assays were performed to determine H3K9me2 enrichment at the myogenin 
promoter in cells expressing vector, Sharp-1, Sharp-1 2KR and Sharp-1 along with SENP1.E-F, ChIP 
assay was performed to determine occupancy of G9a (E), and Sharp-1 (F) at the myogenin promoter in 
cells expressing vector alone, Sharp-1 and Sharp-1 2KR. Error bars indicate mean±SD. 
 
Figure 5. SUMO modified Sharp-1 inhibits MyoD transcriptional activity and function. A, 10T1/2 
cells transfected with MyoD, Myc-Sharp-1 and Myc-Sharp-1 2KR were analyzed for expression of MyoD 
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and Sharp-1 by western blotting. B-D, Myogenic conversion assays were performed in cells transfected 
with MyoD, MyoD and Sharp-1, or MyoD and Sharp-1 2KR. 6 days later, differentiated cells were 
stained with anti-MHC antibody (red). Nuclei were stained with DAPI (B).  Differentiation was quantified 
by plotting myogenic index (C). Troponin T expression was assessed by western blotting (D). E, 10T1/2 
cells were transfected with pMyog-Luc promoter (100ng) together with MyoD (50ng), Sharp-1 (25ng and 
50ng) or Sharp-1 2KR (50ng) as indicated. 48 h later, cells were harvested and assayed for luciferase 
activity. Error bars indicate mean±SD. F, C2C12 cells were transfected with Myc-tagged Sharp-1 and 
Sharp-1 2KR. 24 hr later, lysates were immunoprecipitated and interaction with endogenous MyoD was 
analysed by western blotting with anti-MyoD antibody. Lysates (input) were immunoblotted with anti-
Myc and anti-MyoD antibodies to detect Sharp-1and MyoD expression. 
 
Figure 6. SUMO modification of Sharp-1 is critical for interaction with G9a. A, Alignment of G9a 
cDNA sequence from human, mouse, rat, and zebrafish revealed a conserved SBM (highlighted). B, Cells 
transfected with Flag-G9a, Myc-Sharp-1 or Myc-Sharp-1 2KR, were immunoprecipitated with Myc-
agarose beads, and immunoblotted with anti-Flag and anti-Myc antibodies. Input (lysates) were analysed 
for G9a, and Sharp-1 expression. C, C2C12 cells were transfected with Myc-Sharp-1 or Myc-Sharp-1 
2KR, immunoprecipitated with Myc-agarose beads and endogenous G9a interaction was analysed by 
immunobloting with anti-G9a antibody. Lysates (input) were immunoblotted with anti-G9a and anti-Myc 
antibodies to detect G9a and Sharp-1 expression. D, Cells were transfected with Myc-Sharp-1, Flag-G9a, 
alone or together with SENP1. Lysates were immunoprecipitated and immunoblotted with anti-Flag and 
anti-Myc antibodies. E, 10T1/2 cells were transfected with pMyog-Luc promoter (100ng) together with 
MyoD (50ng), Sharp-1 (50ng), Sharp-1 2KR (50ng) as indicated. 24 h after transfection, UNC0638 was 
added to cells expressing Sharp-1 and Sharp-1 2KR. 24 h later, cells were harvested and analyzed for 
luciferase activity. Error bars indicate mean±SD. 
 
 
 
 






